AU2005323062A1 - Sustained delivery of PDGF using self-assembling peptide nanofibers - Google Patents
Sustained delivery of PDGF using self-assembling peptide nanofibers Download PDFInfo
- Publication number
- AU2005323062A1 AU2005323062A1 AU2005323062A AU2005323062A AU2005323062A1 AU 2005323062 A1 AU2005323062 A1 AU 2005323062A1 AU 2005323062 A AU2005323062 A AU 2005323062A AU 2005323062 A AU2005323062 A AU 2005323062A AU 2005323062 A1 AU2005323062 A1 AU 2005323062A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- peptides
- pdgf
- self
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64099805P | 2005-01-04 | 2005-01-04 | |
| US60/640,998 | 2005-01-04 | ||
| US70231805P | 2005-07-26 | 2005-07-26 | |
| US60/702,318 | 2005-07-26 | ||
| PCT/US2005/046768 WO2006073889A2 (en) | 2005-01-04 | 2005-12-29 | Sustained delivery of pdgf using self-assembling peptide nanofibers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005323062A1 true AU2005323062A1 (en) | 2006-07-13 |
Family
ID=36648006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005323062A Abandoned AU2005323062A1 (en) | 2005-01-04 | 2005-12-29 | Sustained delivery of PDGF using self-assembling peptide nanofibers |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7429567B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1833504A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008526749A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005323062A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2592292A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006073889A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2572964C (en) * | 2004-07-06 | 2018-03-06 | 3D Matrix, Inc. | Purified amphiphilic peptide compositions and uses thereof |
| US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
| KR20100102750A (ko) * | 2005-04-25 | 2010-09-24 | 메사추세츠 인스티튜트 오브 테크놀로지 | 지혈 및 다른 생리학적 활성을 촉진하기 위한 조성물 및 방법 |
| HUE037994T2 (hu) * | 2006-04-25 | 2018-09-28 | Massachusetts Inst Technology | Készítmények és eljárások szennyezõ anyagok, testfolyadékok vagy más anyagok mozgásának befolyásolására és/vagy más fiziológiai állapotok befolyásolására |
| CA2655933C (en) * | 2006-06-23 | 2014-09-09 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| EP2066697A2 (en) * | 2006-09-26 | 2009-06-10 | Massachusetts Institute of Technology | Modified self-assembling peptides |
| US7696309B2 (en) * | 2006-10-23 | 2010-04-13 | The Brigham And Women's Hospital, Inc. | Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| US9187517B2 (en) | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| JP5558104B2 (ja) * | 2006-12-11 | 2014-07-23 | スリー−ディー マトリックス, インコーポレイテッド | 心組織の保護および再生のための組成物および方法 |
| US9415084B2 (en) * | 2007-03-14 | 2016-08-16 | Arch Biosurgery, Inc. | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
| CN105435211A (zh) | 2008-10-06 | 2016-03-30 | 三维肽胶株式会社 | 组织闭塞剂 |
| CN104829714A (zh) | 2008-11-03 | 2015-08-12 | 阿莱斯亚生物疗法股份有限公司 | 特异性地阻滞肿瘤抗原的生物活性的抗体 |
| US20110117195A1 (en) * | 2009-11-18 | 2011-05-19 | National Cheng Kung University | Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers |
| WO2011072482A1 (en) | 2009-12-14 | 2011-06-23 | The University Of Hong Kong | Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells |
| JP5732691B2 (ja) * | 2010-01-14 | 2015-06-10 | 学校法人同志社 | インスリン製剤 |
| WO2011106234A1 (en) | 2010-02-25 | 2011-09-01 | Provasculon, Inc. | Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage |
| CA2893376A1 (en) | 2011-03-31 | 2012-10-04 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof |
| JP6145089B2 (ja) | 2011-06-07 | 2017-06-07 | メソブラスト インターナショナル エスエイアールエル | ストロマ細胞由来因子−1のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法 |
| AU2013209234B2 (en) | 2012-01-09 | 2017-11-09 | Adc Therapeutics Sa | Method for treating breast cancer |
| WO2014004467A1 (en) | 2012-06-25 | 2014-01-03 | The Brigham And Women's Hospital, Inc. | Selective cartilage therapy |
| US9421245B2 (en) | 2012-06-25 | 2016-08-23 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| EP2869903B1 (en) | 2012-07-06 | 2018-11-28 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
| EP2698162A1 (en) | 2012-08-15 | 2014-02-19 | Credentis AG | Method for producing a composition for treating a tooth lesion |
| JP6118905B2 (ja) * | 2012-09-21 | 2017-04-19 | テクノロヒアス アバンサダス インスピラリア ス.ル.Tecnologias Avanzadas Inspiralia S.L.(25) | 心臓修復パッチの新しいスキャフォールド |
| WO2015027203A1 (en) | 2013-08-22 | 2015-02-26 | Arch Biosurgery, Inc. | Implantable meshes for controlling the movement of fluids |
| EP2853256A1 (en) | 2013-09-25 | 2015-04-01 | Credentis AG | Dental care product for tooth whitening |
| ES2669548T3 (es) | 2013-09-25 | 2018-05-28 | Credentis Ag | Producto de cuidado dental para el blanqueamiento de los dientes |
| DK3116896T3 (en) | 2014-03-10 | 2019-03-18 | 3 D Matrix Ltd | SELF-PREPARING PEPTIME COMPOSITIONS |
| ES3037364T3 (en) | 2014-03-10 | 2025-10-01 | 3 D Matrix Ltd | Sterilization and filtration of peptide compositions |
| ES2712608T3 (es) | 2014-03-10 | 2019-05-14 | 3 D Matrix Ltd | Péptidos autoensamblantes para el tratamiento de las bullas pulmonares |
| CN104497107B (zh) * | 2014-12-08 | 2017-09-19 | 重庆医科大学 | 一种自组装短肽及其在细胞三维培养中的应用 |
| CN104693277B (zh) * | 2015-03-26 | 2018-02-13 | 罗忠礼 | 一种自组装短肽及其在细胞三维培养中的应用 |
| CN105148289B (zh) * | 2015-09-30 | 2018-10-09 | 南京中医药大学 | 一种两亲性寡聚多肽药物结合物 |
| CN105288653B (zh) * | 2015-11-19 | 2018-10-09 | 南京中医药大学 | 一种两亲性寡聚多肽药物结合物 |
| WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
| EP3248590A1 (en) | 2016-05-24 | 2017-11-29 | Credentis AG | Personal dental care product for caries treatment |
| EP3248591A1 (en) | 2016-05-24 | 2017-11-29 | Credentis AG | Method and product for caries treatment |
| CN117085140A (zh) | 2017-12-15 | 2023-11-21 | 立美基股份有限公司 | 表面活性剂肽纳米结构及在药物递送中的用途 |
| JP7466876B2 (ja) * | 2019-02-20 | 2024-04-15 | 国立大学法人東京農工大学 | 自己組織化ペプチド |
| EP3831360A1 (en) | 2019-12-04 | 2021-06-09 | Credentis AG | Personal dental care product for preventing demineralisation |
| US11154470B1 (en) | 2020-07-31 | 2021-10-26 | vVardis AG | Anti-inflammatory and senolytic dental care product with tooth whitening characteristics |
| CN114181295B (zh) * | 2021-12-15 | 2023-07-04 | 湖南大学 | 一种多肽衍生物及其用途、水凝胶及其制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5955343A (en) * | 1992-12-28 | 1999-09-21 | Massachusetts Institute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| US5670483A (en) | 1992-12-28 | 1997-09-23 | Massachusetts Insititute Of Technology | Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor |
| JPH08508511A (ja) * | 1993-04-29 | 1996-09-10 | ワシントン・ユニバーシテイー | 副行循環の改善への血小板由来成長因子の使用 |
| JPH11506722A (ja) * | 1995-06-07 | 1999-06-15 | ベイラー・カレッジ・オブ・メディスン | 細胞に核酸を送達するための核酸運搬体 |
| WO2001035932A2 (en) * | 1999-11-18 | 2001-05-25 | The Regents Of The University Of Michigan | Sustained drug delivery from structural matrices |
| WO2002062969A2 (en) * | 2001-02-06 | 2002-08-15 | Massachusetts Institute Of Technology | Cellular reprogramming in peptide hydrogel and uses thereof |
| US7449180B2 (en) * | 2001-02-06 | 2008-11-11 | John Kisiday | Macroscopic scaffold containing amphiphilic peptides encapsulating cells |
| WO2002076344A1 (en) * | 2001-03-23 | 2002-10-03 | Durect Corporation | Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
| US7179784B2 (en) * | 2001-07-10 | 2007-02-20 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| KR20030043780A (ko) | 2001-11-28 | 2003-06-02 | 주식회사 바이오폴리메드 | 생체적합성 비항원성 공중합체와 그 결합체 및 이들의제조방법 |
| US20030139333A1 (en) * | 2002-01-18 | 2003-07-24 | Genetix Pharmaceuticals, Inc. | Methods and compositions for promoting angiogenesis |
| US20040242469A1 (en) * | 2002-05-13 | 2004-12-02 | Lee Richard T. | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
| AU2003274900A1 (en) * | 2002-07-15 | 2004-02-02 | Massachusetts Institute Of Technology | Cellular reprogramming in peptide hydrogel and uses thereof |
| JP2004115413A (ja) * | 2002-09-25 | 2004-04-15 | Yasuhiko Tabata | 冠状動脈狭窄または閉塞治療用徐放性製剤 |
| AU2003297282A1 (en) * | 2002-11-14 | 2004-06-15 | Cornell Research Foundation, Inc. | Protection of cardiac myocardium |
| US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
| US7641643B2 (en) * | 2003-04-15 | 2010-01-05 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| WO2005014615A2 (en) * | 2003-06-25 | 2005-02-17 | Massachusetts Institute Of Technology | Self-assembling peptides incorporating modifications and methods of use thereof |
| CA2572964C (en) * | 2004-07-06 | 2018-03-06 | 3D Matrix, Inc. | Purified amphiphilic peptide compositions and uses thereof |
-
2005
- 2005-12-29 AU AU2005323062A patent/AU2005323062A1/en not_active Abandoned
- 2005-12-29 US US11/320,468 patent/US7429567B2/en not_active Expired - Fee Related
- 2005-12-29 CA CA002592292A patent/CA2592292A1/en not_active Abandoned
- 2005-12-29 JP JP2007549507A patent/JP2008526749A/ja active Pending
- 2005-12-29 EP EP05855348A patent/EP1833504A4/en not_active Withdrawn
- 2005-12-29 WO PCT/US2005/046768 patent/WO2006073889A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20060148703A1 (en) | 2006-07-06 |
| WO2006073889A3 (en) | 2007-06-14 |
| US7429567B2 (en) | 2008-09-30 |
| WO2006073889A2 (en) | 2006-07-13 |
| EP1833504A4 (en) | 2009-08-12 |
| CA2592292A1 (en) | 2006-07-13 |
| JP2008526749A (ja) | 2008-07-24 |
| EP1833504A2 (en) | 2007-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7429567B2 (en) | Sustained delivery of PDGF using self-assembling peptide nanofibers | |
| Liu et al. | A self-assembling peptide hydrogel-based drug co-delivery platform to improve tissue repair after ischemia-reperfusion injury | |
| Wu et al. | An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques | |
| Jia et al. | Cardiovascular effects of a PEGylated apelin | |
| EP2076290B1 (en) | Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis | |
| US7399831B2 (en) | Targeted delivery of biological factors using self-assembling peptide nanofibers | |
| US20110117195A1 (en) | Method for improving myocardial infarction by intramyocardial or transendocardial injection of peptide nanofibers | |
| WO2020081522A1 (en) | Fibroblast activation protein (fap) targeted imaging and therapy in fibrosis | |
| CN110603260B (zh) | Npra激动剂、组合物及其用途 | |
| Wang et al. | Cascaded bio-responsive delivery of eNOS gene and ZNF580 gene to collaboratively treat hindlimb ischemia via pro-angiogenesis and anti-inflammation | |
| AU2026201537A1 (en) | Alginate-based microcapsulation for the delivery of alpha-CGRP in cardiovascular diseases | |
| AU2006308989A1 (en) | Novel protein transduction domains and uses therefor | |
| Nguyen et al. | Local release of NECA (5′-(N-ethylcarboxamido) adenosine) from implantable polymeric sheets for enhanced islet revascularization in extrahepatic transplantation site | |
| US20240197896A1 (en) | Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery | |
| EP1501535A1 (en) | Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents | |
| CN120456915A (zh) | 保存和保护心肌细胞以及减少心脏损伤后心脏纤维化的方法 | |
| US20220257711A1 (en) | PEPTOID-PEPTIDE HYBRID, NMEG-aCGRP, AND ITS USE IN CARDIOVASCULAR DISEASES | |
| WO2018022929A1 (en) | Gel-bound compositions for radiotherapy and uses thereof | |
| Zhao et al. | Salvianolic acid B, a novel GLS1 accelerator, alleviates defective endothelial glutaminolysis contributes to impaired angiogenesis and poor ischemic tissue repair in diabetes | |
| JP2025532522A (ja) | 新規血小板由来増殖因子ペプチド模倣物 | |
| US20210236668A1 (en) | Compositions for radiotherapy and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |